Fulgent Genetics, Inc. Operating Income Loss

• Fulgent Genetics, Inc. showed a decrease of -23.2% in Operating Income Loss from 2024 to 2025.
• This data is from Fulgent Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 12 years of available data (2014 to 2025), Fulgent Genetics, Inc.'s Operating Income Loss has declined by 9,101.6%.
• Historical annual values: Fiscal year 2025: -$91.10 million | Fiscal year 2024: -$73.92 million | Fiscal year 2023: -$195.53 million | Fiscal year 2022: $178.53 million | Fiscal year 2021: $675.95 million | Fiscal year 2020: $290.16 million | Fiscal year 2019: -$428.0 thousand | Fiscal year 2018: -$5.07 million | Fiscal year 2017: -$3.48 million | Fiscal year 2016: $918.0 thousand | Fiscal year 2015: -$5.01 million | Fiscal year 2014: -$990.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026